{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:39:29Z","timestamp":1757705969747},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,8,12]],"date-time":"2011-08-12T00:00:00Z","timestamp":1313107200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1752-1947-5-367","type":"journal-article","created":{"date-parts":[[2011,8,12]],"date-time":"2011-08-12T14:17:02Z","timestamp":1313158622000},"source":"Crossref","is-referenced-by-count":2,"title":["Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report"],"prefix":"10.1186","volume":"5","author":[{"given":"Eleftheria","family":"Panteliou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morag","family":"Naysmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,12]]},"reference":[{"key":"1807_CR1","unstructured":"UK Medicines and Healthcare Products Regulatory Agency: Intravenous zoledronic acid: adverse effects on renal function.\n                    http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON087704"},{"key":"1807_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.bone.2003.07.007","volume":"33","author":"E Van Beek","year":"2003","unstructured":"Van Beek E, Cohen L, Leroy I, Ebetino F, L\u00f6wik C, Papadopoulos S: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003, 33: 805-811. 10.1016\/j.bone.2003.07.007.","journal-title":"Bone"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso S, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmakokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002, 42: 1228-1236. 10.1177\/009127002762491316.","journal-title":"J Clin Pharmacol"},{"key":"1807_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.mehy.2005.03.012","volume":"65","author":"S Omoigui","year":"2005","unstructured":"Omoigui S: Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses. 2005, 65: 559-569. 10.1016\/j.mehy.2005.03.012.","journal-title":"Med Hypotheses"},{"key":"1807_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/107999003322558782","volume":"23","author":"G Dicuonzo","year":"2003","unstructured":"Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G: Fever after zoledronic acid administration is due to increase in TNF- and IL-6. J Interferon Cytokine Res. 2003, 23: 649-654. 10.1089\/107999003322558782.","journal-title":"J Interferon Cytokine Res"},{"key":"1807_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ahj.2007.09.006","volume":"155","author":"GM Marcus","year":"2008","unstructured":"Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE: Interleukin 6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008, 155: 303-309. 10.1016\/j.ahj.2007.09.006.","journal-title":"Am Heart J"},{"key":"1807_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckbert","year":"2008","unstructured":"Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM: Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008, 168: 826-831. 10.1001\/archinte.168.8.826.","journal-title":"Arch Intern Med"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Chung Leung P, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med. 2007, 356: 1809-1822. 10.1056\/NEJMoa067312.","journal-title":"New Engl J Med"},{"key":"1807_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/eurheartj\/ehi645","volume":"27","author":"CJ Boos","year":"2006","unstructured":"Boos CJ, Anderson RA, Lip GY: Is atrial fibrillation an inflammatory disorder?. Eur Heart J. 2006, 27: 136-149.","journal-title":"Eur Heart J"},{"key":"1807_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0196-0644(99)70265-9","volume":"34","author":"J Niemann","year":"1999","unstructured":"Niemann J, Cairns C: Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: possible culprits for postcountershock arrhythmias?. Ann Emerg Med. 1999, 34: 1-7. 10.1016\/S0196-0644(99)70265-9.","journal-title":"Ann Emerg Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-5-367\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-5-367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:16:38Z","timestamp":1548126998000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-5-367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,12]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-5-367","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,12]]},"article-number":"367"}}